Skip to main content

Table 2 Clinical and neuropsychological data in memantine intervention and placebo

From: Memantine for the patients with mild cognitive impairment in Parkinson’s disease: a pharmacological fMRI study

 

Placebo

Memantine

P value

UPDRS part3

17.0 ± 6.6

18.0 ± 5.2

N.S.

ESS

7.1 ± 3.8

8.9 ± 5.0

P = 0.07

MMSE

26.1 ± 2.2

25.4 ± 2.5

N.S.

MoCA

20.1 ± 3.1

18.7 ± 4.1

N.S.

PASAT

21.4 ± 7.1

19.8 ± 6.7

N.S.

TMT-A

69.5 ± 21.4

86.6 ± 38.5

P < 0.05

TMT-B

259.4 ± 121.9

312.9 ± 132.6

N.S.

0-back test (number)

17.1 ± 2.3

16.3 ± 4.1

N.S.

1-back test (number)

14.9 ± 3.4

13.9 ± 2.9

N.S.

2-back test (number)

12.4 ± 4.6

10.2 ± 3.9

P < 0.05

0-back test (seconds)

790.3 ± 155.4

800.6 ± 179.1

N.S.

1-back test (seconds)

991.7 ± 171.5

1015.4 ± 208.7

N.S.

2-back test (seconds)

1087.4 ± 208.7

1167.9 ± 274.0

N.S.

  1. This table shows the comparison of neuropsychological findings between memantine intervention and placebo. ESS: Epworth Sleepiness Score; 0-back test (number): number of correct answers in 0-back test (minimum 0, maximum 20); 1-back test (number): number of correct answers in 1-back test (minimum 0, maximum 20); 2-back test (number): number of correct answers in 2-back test (minimum 0, maximum 20); 0-back test (seconds): reaction time of 0-back test; 1-back test (seconds): reaction time of 1-back test; 2-back test (seconds): reaction time of 2-back test; N.S. not significant
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us